Clinical Trial

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.
Protocol Amendment History 5 changes
notable Trial sites expanded: 63 -> 67 locations 2026-07-30
notable Trial sites expanded: 56 -> 61 locations 2026-07-02
notable Trial sites expanded: 50 -> 56 locations 2026-06-09
notable Trial sites expanded: 45 -> 48 locations 2026-05-16
notable Trial sites expanded: 42 -> 45 locations 2026-05-01
Trial Details
NCT Number NCT07003425
Lead Sponsor Apogee Therapeutics, Inc.
Conditions Atopic Dermatitis
Enrollment 350 participants
Start Date 2025-05-14
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29